P1646Safety and efficacy of second generation everolimus-eluting stents versus biolimus-eluting stents versus zotarolimus-eluting stents in real world practice
نویسندگان
چکیده
منابع مشابه
Clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents versus durable polymer everolimus-eluting Xience stents
There are limited data about clinical outcomes of biodegradable polymer biolimus-eluting BioMatrix stents (BP-BES) and durable polymer everolimus-eluting Xience stents (DP-EES) in real world practice. We sought to compare the clinical outcomes of BP-BES and DP-EES in real world cohorts of patients undergoing percutaneous coronary intervention. A prospective multicenter registry enrolled 999 pat...
متن کاملone-year outcome of everolimus-eluting stents versus biolimus-eluting stents in patients undergoing percutaneous coronary intervention
background: the biolimus-eluting stent (bes), with a biodegradable polymer, has not been previously compared with the everolimus-eluting stent (ees), as a second-generation drug-eluting stent (des).we sought to compare the 1-year outcome between the promus ™ stent (ees type) and the biomatrix ™ stent (bes type). methods: from march 2008 to september 2011, all patients treated with the promus™ s...
متن کاملSafety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
BACKGROUND Although new-generation drug-eluting stents represent the standard of care among patients undergoing percutaneous coronary intervention, there remains debate about differences in efficacy and the risk of stent thrombosis between the Resolute zotarolimus-eluting stent (R-ZES) and the everolimus-eluting stent (EES). The aim of this study was to evaluate the safety and efficacy of the R...
متن کاملComparison of zotarolimus-eluting and everolimus-eluting coronary stents.
BACKGROUND New-generation coronary stents that release zotarolimus or everolimus have been shown to reduce the risk of restenosis. However, it is unclear whether there are differences in efficacy and safety between the two types of stents on the basis of prospectively adjudicated end points endorsed by the Food and Drug Administration. METHODS In this multicenter, noninferiority trial with mi...
متن کاملA randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
OBJECTIVES The aim of this study was to compare the safety and efficacy of Resolute zotarolimus-eluting stents (ZES) (Medtronic Cardiovascular, Santa Rosa, California) with Xience V everolimus-eluting stents (EES) (Abbott Vascular Devices, Santa Clara, California) at 1-year follow-up. BACKGROUND Only 1 randomized trial previously compared these stents. METHODS This investigator-initiated, p...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Heart Journal
سال: 2018
ISSN: 0195-668X,1522-9645
DOI: 10.1093/eurheartj/ehy565.p1646